Trade

with

AVEO Pharmaceuticals Inc
(NASDAQ: AVEO)
AdChoices
=
1.04
0.00
0.00%
After Hours :
-
-
-

Open

1.08

Previous Close

1.04

Volume (Avg)

154.73k (376.56k)

Day's Range

1.03-1.09

52Wk Range

0.8500-2.35

Market Cap.

54.39M

Dividend Rate ( Yield )

-

Beta

1.06

Shares Outstanding

52.30M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Sell
    • Revenue

    • 1.29M

    • Net Income

    • -107.03M

    • Market Cap.

    • 54.39M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -368.03

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.06

    • Forward P/E

    • -1.28

    • Price/Sales

    • 3.02

    • Price/Book Value

    • 1.16

    • Price/Cash flow

    • -0.81

      • EBITDA

      • -100.13M

      • Return on Capital %

      • -44.42

      • Return on Equity %

      • -83.97

      • Return on Assets %

      • -44.42

      • Book Value/Share

      • 0.90

      • Shares Outstanding

      • 52.30M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Sell
        • 1 Year Price Target

        • 2.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -0.78

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 469.80

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -41.98

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -368.03

            • 39.38

            • Net Profit Margin

            • -368.03

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -1,839.40

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -1,839.30

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.07

              • 0.76

              • Current Ratio

              • 2.59

              • 2.92

              • Quick Ratio

              • 2.46

              • 2.35

              • Interest Coverage

              • -25.02

              • 38.02

              • Leverage Ratio

              • 2.22

              • 2.21

              • Book Value/Share

              • 0.90

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -0.82

                • 196.08

                • P/E Ratio 5-Year High

                • -16.98

                • 634.30

                • P/E Ratio 5-Year Low

                • -0.67

                • 124.82

                • Price/Sales Ratio

                • 3.02

                • 9.12

                • Price/Book Value

                • 1.16

                • 8.26

                • Price/Cash Flow Ratio

                • -0.81

                • 47.39

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -83.97

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -44.42

                    (-47.30)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -64.89

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.12

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -103.90M
                  Operating Margin
                  -8,035.89
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -0.81
                  Ownership

                  Institutional Ownership

                  47.12%

                  Top 10 Institutions

                  34.41%

                  Mutual Fund Ownership

                  6.25%

                  Float

                  85.35%

                  5% / Insider Ownership

                  2.78%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Total Stock Mkt Idx

                  •  

                    814,566

                  • 0.00

                  • 1.56

                  • Vanguard VIF Small Comp Gr

                  •  

                    498,621

                  • 0.00

                  • 0.95

                  • Vanguard Instl Total Stock Market Index

                  •  

                    412,100

                  • 0.00

                  • 0.79

                  • Vanguard Extended Market Index Fund

                  •  

                    390,319

                  • 8.00

                  • 0.75

                  • TFS Market Neutral Fund

                  •  

                    341,835

                  • 139.30

                  • 0.65

                  • Fidelity Spartan® Extended Mkt Indx Fd

                  •  

                    170,406

                  • 0.00

                  • 0.33

                  • iShares Micro-Cap

                  •  

                    148,692

                  • 1.28

                  • 0.27

                  • DFA U.S. Small Cap Portfolio

                  •  

                    126,042

                  • 0.00

                  • 0.24

                  • DFA U.S. Micro Cap Portfolio

                  •  

                    75,858

                  • 0.00

                  • 0.15

                  • EB DL Non-SL Market Completion Fund

                  •  

                    59,843

                  • 1,100.94

                  • 0.11

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Baupost Group LLC

                  •  

                    3,829,350

                  • 0.00%

                  • 7.32

                  • Sarissa Capital Management LP

                  •  

                    2,570,759

                  • 0.00%

                  • 4.91

                  • Great Point Partners LLC

                  •  

                    2,325,000

                  • -18.89%

                  • 4.45

                  • BlackRock Fund Advisors

                  •  

                    2,165,142

                  • -13.90%

                  • 4.14

                  • Vanguard Group, Inc.

                  •  

                    1,470,970

                  • -3.90%

                  • 2.81

                  • MPM Capital L.P.

                  •  

                    1,372,118

                  • -37.88%

                  • 2.65

                  • Renaissance Technologies Corp

                  •  

                    1,343,488

                  • +5.33%

                  • 2.57

                  • Palo Alto Investors, LLC

                  •  

                    1,200,800

                  • -57.99%

                  • 2.30

                  • D. E. Shaw & Co LP

                  •  

                    1,030,292

                  • -6.90%

                  • 1.97

                  • Granahan Investment Management Inc..

                  •  

                    676,451

                  • 0.00%

                  • 1.29

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Value

                  AVEO Pharmaceuticals Inc was incorporated under the laws of the State of Delaware on October 19, 2001 as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. on March 1, 2005. The Company is a cancer thera...morepeutics company that discovers, develops and commercializes targeted cancer therapies to impact patients’ lives. The Company’s proprietary Human Response Platform provides the company unique insights into cancer and related disease biology and is being leveraged in the discovery and clinical development of its therapeutic candidates. Its product under development include: AV-203, an anti-ErbB3 monoclonal antibody with broad therapeutic potential. Ficlatuzumab, is a Hepatocyte Growth Factor, or HGF, inhibitory antibody. Tivozanib, is an investigational tyrosine kinase inh...moreibitor of all three vascular endothelial growth factor, or VEGF receptors. AV-380, a potential first-in-class GDF-15 inhibitor, was discovered using proprietary Human Response Platform, that provides the company unique insights into cancer and related disease biology. The Company competes with Roche Laboratories, Inc., Pfizer Inc., Bayer HealthCare AG, Sanofi-Aventis, US, LLC, Amgen, Inc. and GlaxoSmithKline plc. The Company contracts with third parties for the manufacture of clinical product candidates. On March 9, 2014, Company entered into a manufacturing agreement with AbbVie Inc. for the process and development of AV-380. In August 2010, it entered into an agreement with Gallus BioPharmaceuticals, LLC for the clinical manufacture of AV-203 drug substance. The Company seeks trademark protection in the U.S. and foreign jurisdictions where available and when appropriate.lessless

                  Key People

                  Tuan Ha-Ngoc

                  CEO/CFO/Director/President

                  Mr. Henri A. Termeer

                  Chairman of the Board/Director

                  Mr. Matthew Dallas

                  Chief Accounting Officer/Treasurer/Vice President, Divisional

                  Dr. Anthony B. Evnin,PhD

                  Director

                  Dr. Raju S. Kucherlapati,PhD

                  Director

                  • AVEO Pharmaceuticals Inc

                  • 650 East Kendall Street

                  • Cambridge, MA 02142

                  • USA.Map

                  • Phone: +1 617 299-5000

                  • Fax: -

                  • aveooncology.com

                  Incorporated

                  2001

                  Employees

                  71

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: